Barazeghi E, et al. - Using 40 primary tumors and 47 corresponding metastases, an analysis was conducted to examine the possible involvement of 5-hydroxymethylcytosine (5hmC), TET1 and TET2 in small intestinal neuroendocrine tumors (SI-NETs). By DNA immune-dot blot assay and immunohistochemistry, the level of 5hmC, TET1 and TET2 were examined. Researchers reported that SI-NETs were epigenetically dysregulated at the level of 5-hydroxymethylcytosine/ TET1/TET2. They suggested that KPT-330/selinexor should be considered and evaluated for potential treatments in patients with SI-NET disease and furthermore in combinations with somatostatin analogues, peptide receptor radiotherapy, or everolimus.